CAMK2A and schizophrenia: Interestingly, regional differences in phospholipase C isoenzyme (Plcb1, Plcb4), druggable targets identified in the Camk2a proteome, expression in the brain are known to underlie several brain disorders including epilepsy, schizophrenia, and AD47.